Sunday, November 11: 8:00 AM - 1:30 PM
The U.S. Food and Drug Administration in April of 2017 allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. Although these are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual’s genetic predisposition to a few medical diseases or conditions, the FDA is very specific about the fact that results obtained from genetic tests should not be used for diagnosis or to inform treatment decisions. Instead, users should consult a health care professional with questions or concerns about results.

It is obvious now that genomics tests need to be supplemented with functional biochemistry tests that are more reflective of characterizing disease states, health conditions, performance and lifestyle. Our deuterobolomics workshop introduces clinical and laboratory methods to measure critical metabolic outputs, organic acid turnover by deuterium and 13C measurements in metabolites from urine, saliva and breath. Ketobolomics and Deuterobolomics tests enhance medical practices with contemporary metabolomics services to include ketogenic dietary interventions and deuterium depleting protocols based on scientific (B) and academic evidence (C) in medical practices. Published studies and de-identified clinical data using stable isotope based methods are discussed and these methods have been reviewed by the FDA as safe and effective tools for metabolic studies to enhance transitional and integrative medicine and clinics. 

Laszlo Boros, MD

Dr. Boros holds a Doctor of Medicine (M.D.) degree from the Albert Szent-Györgyi School of Medicine, Szeged, Hungary. Dr. Boros is currently a Professor of Pediatrics, Endocrinology and Metabolism at the UCLA School of Medicine, investigator at the UCLA Clinical & Translational Science (CTSI) and the Los Angeles Biomedical Research Institutes, and he is also the Chief Scientific Advisor of SiDMAP, LLC. Dr. Boros is the co-inventor of the stable isotope-based dynamic metabolic profiling (SIDMAP) technology. The core technology involves studying natural and disease/drug induced variations in stable non-radiating harmless isotope variations and cross talk among metabolites in living systems with 13C-glucose. Dr. Boros is the co-inventor of the targeted 13C tracer fate association study (TTFAS) platform to study the oncoisotope role of deuterium and its depletion by mitochondrial matrix water exchanges to prevent oncoisotopic cell transformation by deuterium. Dr. Boros trained as a house staff in his medical school in gastroenterology after receiving a research training fellowship from the Hungarian Academy of Sciences. Dr. Boros was a visiting Scholar at the Essen School of Medicine in Germany and also worked as a Research Scientist at the Ohio State University, Department of Surgery, in the historic Zollinger-Ellison laboratory. 

Dr. Boros has indicated that he has no financial relationships with any commercial supporters.


1.888.995.3088  |  info@ameetingbydesign.com

1.800.532.3688  |  info@acam.org  |  www.acam.org